Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Treatment of Antiphospholipid Antibody Syndrome (APS) in Pregnancy: A Randomized Pilot Trial Comparing Low Molecular Weight Heparin to Unfractionated Heparin

Abstract

Objective To compare low molecular weight heparin (LMWH), specifically dalteparin, to unfractionated heparin (UFH) for the treatment of antiphospholipid antibody syndrome (APS) in pregnancy.Methods In a tertiary referral centre, 28 women met the 1999 International Consensus Criteria for APS, based on their obstetrical history and APS serology. The women were randomized, using a random numbers table with blocks of 12, to receive either prophylactic dosing of dalteparin or UFH starting either preconceptionally or early in pregnancy. All women also received low-dose acetylsalicylic acid, started preconceptionally. The primary outcome was a live birth. The secondary outcomes were maternal and fetal complications.Results Of the 14 women who received the LMWH, dalteparin, and the 14 women who received UFH, 1 woman in each group did not conceive. Nine of the 13 women (69%) given dalteparin had a successful pregnancy (95% confidence interval [CI], 39-91%), compared to 4 out of the 13 women (31%) in the UFH group (95% CI, 9-61%). Nine women in total had spinal or epidural anaesthesia, and there were no complications overall.Conclusion Dalteparin may be an effective alternative to UFH for treatment of APS in pregnancy. A multicentre randomized trial is needed to determine benefit-to-risk ratios for the use of dalteparin and UFH to treat this high-risk obstetrical condition. Pharmacokinetic and pharmacodynamic studies are also recommended to maximize therapeutic response and minimize toxicity.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1701-2163(16)30644-2

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. 1998, Antiphospholipid syndrome, ACOG Educational Bulletin, 244, 151

Cited by

See all 140

Metadata

Authors
Stephenson, M. D., Ballem, P. J., Tsang, P., Purkiss, S., Ensworth, S., Houlihan, E., & Ensom, M. H. H.
Affiliations
  • University of British Columbia (CA)
  • B.C. Women's Hospital & Health Centre (CA)
Venue
Journal of Obstetrics and Gynaecology Canada
Publisher
Elsevier BV
Published
2004-08
Volume
26
Issue
8
Pages
729-734
ISSN
1701-2163 (ISSN-L)
OpenAlex
W117666081
Cited by
140
References
30
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 2 · 2021: 4 · 2020: 1 · 2019: 7 · 2018: 5 · 2017: 9 · 2016: 2 · 2015: 5 · 2014: 14 · 2013: 9 · 2012: 12
FWCI
3.11
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • Journal of Obstetrics and Gynaecology Canada (publishedVersion)
  • PubMed (publishedVersion)
Funders
University of British Columbia
Topics
  • Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
  • Life Sciences › Immunology and Microbiology › Immunology › Reproductive System and Pregnancy
  • Health Sciences › Medicine › Hematology › Heparin-Induced Thrombocytopenia and Thrombosis
Keywords
antiphospholipid syndrome, pregnancy, dalteparin, low molecular weight heparin, unfractionated heparin, anticoagulation, live birth, aspirin, maternal complications, fetal complications
MeSH terms
Adult, Anticoagulants, Aspirin, Female, Heparin, Humans, Pilot Projects, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Antiphospholipid Syndrome, Preconception Care, Dalteparin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Antiphospholipid Antibody Syndrome (APS) in Pregnancy: A Randomized Pilot Trial Comparing Low Molecular Weight Heparin to Unfractionated Heparin. https://app.cochat.ai/papers/10.1016/s1701-2163(16)30644-2
The paper
Stephenson, M. D., Ballem, P. J., Tsang, P., Purkiss, S., Ensworth, S., Houlihan, E., & Ensom, M. H. H. (2004). Treatment of Antiphospholipid Antibody Syndrome (APS) in Pregnancy: A Randomized Pilot Trial Comparing Low Molecular Weight Heparin to Unfractionated Heparin. Journal of Obstetrics and Gynaecology Canada. https://doi.org/10.1016/s1701-2163(16)30644-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.